King's College London
Francesco Dazzi focuses on Mesenchymal stem cell, Stem cell, Immunology, Cell biology and Internal medicine. He combines subjects such as Clinical uses of mesenchymal stem cells, Stromal cell, Cancer stem cell, Cell cycle and Bone marrow with his study of Mesenchymal stem cell. His Stem cell research integrates issues from Endothelial stem cell, Adult stem cell and T cell.
As part of his studies on Immunology, Francesco Dazzi frequently links adjacent subjects like Cytotoxic T cell. His biological study spans a wide range of topics, including IL-2 receptor and Antigen-presenting cell. His Internal medicine research is multidisciplinary, relying on both In vitro and Surgery.
His scientific interests lie mostly in Immunology, Mesenchymal stem cell, Stem cell, Transplantation and Internal medicine. His Mesenchymal stem cell study is concerned with the larger field of Cell biology. His Cell biology research focuses on subjects like IL-2 receptor, which are linked to T lymphocyte.
The various areas that Francesco Dazzi examines in his Stem cell study include Pathology and Adult stem cell. His work deals with themes such as Cell therapy, Histocompatibility and Intensive care medicine, which intersect with Transplantation. His Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology.
Francesco Dazzi mostly deals with Mesenchymal stem cell, Cancer research, Stromal cell, Immune system and Transplantation. The study incorporates disciplines such as Cytotoxic T cell and Internal medicine, Clinical trial in addition to Mesenchymal stem cell. His studies deal with areas such as Cancer, Stem cell and Apoptosis as well as Cancer research.
His Stem cell research includes elements of Chronic myelogenous leukemia and Bone marrow. His Immune system study also includes
Francesco Dazzi mainly focuses on Mesenchymal stem cell, Stromal cell, Clinical trial, Internal medicine and Cancer research. He has researched Stromal cell in several fields, including Myeloid, Stem cell, Cell biology and Immune system. Francesco Dazzi carries out multidisciplinary research, doing studies in Stem cell and Chemistry.
Francesco Dazzi interconnects Inflammation, Reprogramming, Tissue homeostasis and Cell type in the investigation of issues within Cell biology. His Clinical trial research is multidisciplinary, incorporating elements of Disease, Inflammatory bowel disease and Oncology. Bone marrow and Intestinal mucosa are among the areas of Internal medicine where he concentrates his study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
Mauro Krampera;Sarah Glennie;Julian Dyson;Diane Scott.
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.
Sarah Glennie;Inês Soeiro;Peter J. Dyson;Eric W.-F. Lam.
Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.
Rajesh Ramasamy;Henrietta Fazekasova;Eric W.-F. Lam;In s Soeiro.
The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden)
Paolo Simioni;Paolo Prandoni;Anthonie W.A. Lensing;Alberta Scudeller.
The New England Journal of Medicine (1997)
Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth.
R Ramasamy;E. W. F. Lam;I. Soeiro;Veronica Tisato.
The role of mesenchymal stem cells in haemopoiesis.
Francesco Dazzi;Rajesh Ramasamy;Sarah Glennie;Simon P. Jones.
Blood Reviews (2006)
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.
Antonio Galleu;Yanira Riffo-Vasquez;Cristina Trento;Cara Lomas.
Science Translational Medicine (2017)
Mesenchymal stem cells: the fibroblasts' new clothes?
Muzlifah A. Haniffa;Matthew P. Collin;Christopher D. Buckley;Francesco Dazzi.
Characterization and Clinical Application of Human CD34+ Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colony-Stimulating Factor
Myrtle Y. Gordon;Nataša Levičar;Madhava Pai;Philippe Bachellier.
Stem Cells (2006)
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
David Marin;Dragana Milojkovic;Eduardo Olavarria;Jamshid S. Khorashad.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: